Business
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) on track for 2H 2026 Cash runway expected to be sufficient to fund operations through clinical readouts and into Q4 2026 HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the deve
About this update from Tvardi Therapeutics, Inc.
[{"type":"image","alt":"Tvardi Therapeutics","displaySize":"","headline":null,"caption":"Tvardi Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":158,"url":"https://media.zenfs.com/en/globenewswire.com/a80bef36d293f8d945f0fd2a8230516a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/v11.qHOvz06m91J_zyDSiw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMQ--/https://media.zenfs.com/en/globenewswire.com/a80bef36d293f8d945f0fd2a8230516a","width":300,"height":158},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/v11.qHOvz06m91J_zyDSiw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMQ--/https://media.zenfs.com/en/globenewswire.com/a80bef36d293f8d945f0fd2a8230516a","width":300,"height":158}},"lazy":false},{"type":"text","content":"Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June","length":150,"tagName":"p"},{"type":"text","content":"Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) on track for 2H 2026","length":98,"tagName":"p"},{"type":"text","content":"Cash runway expected to be sufficient to fund operations through clinical readouts and into Q4 2026","length":104,"tagName":"p"},{"type":"text","content":"HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its financial and operating results for the first quarter ended March 31, 2026, and provided a business update.","length":397,"tagName":"p"},{"type":"text","content":"Recent Progress and Upcoming Catalysts:","length":39,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"TTI-109 (Healthy Volunteer Study): Study ongoing with topline data anticipated in June 2026. The Company plans to announce the clinical development strategy based on these results.","length":180,"tagName":"p"}]},{"val":[{"type":"text","content":"TTI-101 (HCC – REVERT LIVER CANCER study): Phase 1b/2 trial remains on track to report topline results in 2H 2026.","length":114,"tagName":"p"}]},{"val":[{"type":"text","content":"TTI-101 (IPF – REVERT IPF study additional analyses): Phase 2 trial showed that TTI-101 was associate...